Video

Dr. Jang on current state of immunotherapy in advanced GU cancers

Author(s):

Urology Times staff
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Albert Jang, MD, a 3rd-year internal resident physician at Tulane University, discusses progress and unmet needs with immunotherapy for the treatment of patients with genitourinary cancers.

      Related Videos
      Martin Sanda, MD, considers potential future advancements in urology
      Martin Sanda, MD, considers potential future advancements in urology
      Daniel Carson, MD, MS, answers a question during a Zoom video interview
      Dr. Daniel Carson on telehealth vs in-person urology visits
      Laura Bukavina, MD, on the need to integrate mental health support in GU cancer care
      Laura Bukavina, MD, on the need to integrate mental health support in GU cancer care
      Study: GU cancer survivors report difficulty affording mental health, dental care
      Study: GU cancer survivors report difficulty affording mental health, dental care
      Dr. Cary details the history of IU’s testicular cancer program
      Dr. Cary details the history of IU’s testicular cancer program
      Dr. Neal E. Rowe in an interview with Urology Times
      Dr. Rowe highlights AUA course on the management of adrenal tumors
      Dr. Rowe on potential future work with incidental adrenal tumors
      Dr. Rowe on potential future work with incidental adrenal tumors
      Developments in the penile cancer treatment paradigm
      Developments in the penile cancer treatment paradigm
      Why clinicians should join the Global Society of Rare Genitourinary Tumors
      Why clinicians should join the Global Society of Rare Genitourinary Tumors
      Dr. Spiess and Dr. Necchi on new society for rare GU cancers
      Dr. Spiess and Dr. Necchi on new society for rare GU cancers
      Related Content
      Urologist speaking with a male patient following a diagnosis of cancer. | Credit: Adobe Stock
      February 4th 2025

      Urologic Cancer Facts and Updates for World Cancer Day 2025

      Patrick Campbell
      A list of facts and trends to know about the current landscape of urologic cancer management and research in the US.
      Destigmatizing Urology: Dr. Pettaway discusses penile cancer
      March 29th 2022

      Destigmatizing Urology: Dr. Pettaway discusses penile cancer

      Urology Times staff
      “When you compound the patient delay and…the physician delay, then you really get a delay in diagnosis,” says Curtis A. Pettaway, MD.
      FDA approves subcutaneous nivolumab for solid tumors, including RCC
      December 27th 2024

      FDA approves subcutaneous nivolumab for solid tumors, including RCC

      Hannah Clarke
      The approval is supported by data from the phase 3 CheckMate-67T trial.
      Dr. Richard Matulewicz discusses smoking cessation counseling and treatment among urologists
      March 31st 2021

      Dr. Richard Matulewicz discusses smoking cessation counseling and treatment among urologists

      Urology Times staff
      “Because so many disease processes that we deal with are related to tobacco use and smoking specifically… I think this is absolutely our domain,” says Richard S. Matulewicz, MD, of tobacco cessation counseling and treatment.
      Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
      September 24th 2024

      The role of surgery continues to evolve in seminoma

      Jiping Zeng, MD Timothy A. Masterson, MD Clint Cary, MD, MBA, MPH
      "RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.
      BL-B01D1 shows favorable phase 2 efficacy, safety for urothelial carcinoma
      September 14th 2024

      BL-B01D1 shows favorable phase 2 efficacy, safety for urothelial carcinoma

      Kevin Kunzmann
      Investigators observed promising clinical effect with the EGFR / HER3 bispecific antibody-drug conjugate.
      © 2025 MJH Life Sciences

      All rights reserved.